A special moment for BolusCare: I'm flying to Boston these days to present BolusCare to an American professional audience for the first time, from September 26-30, 2026 — at the ASTRO Annual Meeting, the world's largest congress for radiation oncology.
ASTRO is the ideal place for us to talk with radiation oncologists, medical physicists and radiation therapists from across the US, to show BolusCare live, and to learn first-hand what everyday clinical practice in the US expects from patient-specific bolus solutions.
One important note up front: BolusCare is CE-marked as a Class I medical device under MDR (EU) 2017/745 in the European Union, but it is not yet cleared or approved by the FDA in the United States. Our presence at ASTRO is therefore primarily about professional exchange and exploring the market — not about selling or marketing BolusCare as a product available in the US.
We're looking forward to many conversations in Boston, to feedback from a market that's new to us, and to planning the next steps toward a possible US market clearance together with our team. If you're at ASTRO 2026, please come say hello.